**Appendix Table E3. Sample selection criteria and allowed co-interventions for included fibromyalgia observational studies**

| **Author, Year, Country, Funder** | **Diagnostic Criteria** | **Additional Inclusion Criteria** | **Exclusion Criteria** | **Disallowed Pharmaceuticals, Nutraceuticals, or** **Co-interventions** | **Allowed Pharmaceuticals, Nutraceuticals, or Co-interventions** |
| --- | --- | --- | --- | --- | --- |
| **Pharmacologic** |  |  |  |  |  |
| Arnold, 201239USA, CanadaIndustry funded | 1990 ACR criteria | -Male & Female-18-70y-Score ≥ 4 on FIQ physical function raw score (range: 0-33) at screening and between 40-90 on VAS pain scale (range: 0-100) during 14-d baseline period | -Other rheumatic or medical disorders with symptoms similar to FM-Previous exposure to milnacipran-Treatment with an investigational drug within 30 days of screening-BDI >25 (moderate-to-severe depressive symptoms) or current MDD as assessed by MINI-Significant risk of suicide-History of psychosis, hypomania, or mania-Substance abuse-Other severe psychiatric disorder as assessed by investigator-History of behavior that would prohibit compliance for duration of study as assessed by investigator-Pregnancy or breastfeeding-Unacceptable contraception-Any active or unstable medical condition-Prostate enlargement or other genitourinary disorder-Active or pending disability claim, worker’s compensation claim, or litigation | -Digitalis-Centrally acting medications for FM-Transcutaneous electrical nerve stimulation, biofeedback, tender and trigger point injections, acupuncture, and anesthetic or narcotic patches | -Acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents-Short term pain rescue medication included tramadol or hydro-codone between randomization and week 4-Triptans permitted for acute migrant treatment-Nonbenzodiazepine hypnotic agents for treatment of insomnia |
| Younger, 200940USANonprofit/ foundation funded | 1990 ACR criteria | -Held drug dosages steady for at least 2 previous months | -Joint pain/inflammation-History of autoimmune or rheumatologic condition-Blood test results: RF >20IU/mL, antinuclear antibody >1:80, and ESR >60 mm/hour | -Current or recent use of opioids | -Medications other than opioids-Asked not to modify pain treatment regimen without notifying study personnel |
| **Physical** |  |  |  |  |  |
| Drexler, 200241AustriaFunding not reported | 1990 ACR criteria | Not reported | Not reported | Not reported | Not reported |
| **Mixed** |  |  |  |  |  |
| Joshi, 200942IndiaNo external funding support | 1990 ACR criteria | -Male & Female-18-60 years-Symptoms of chronic muscular pain for at least 12 weeks | -Pregnant or lactating-History of trauma, fractures, fever, malignancy, chronic renal or hepatic disorders-Alcohol abuse-Cerebrovascular or neurological abnormality | Not reported | -Allowed to continue previous medications and exercise regimens, if any |

**Abbreviations:** ACR=American College of Rheumatology; BDI=Beck Depression Inventory; ESR=erythrocyte sedimentation rate; FIQ=Fibromyalgia Impact Questionnaire; FM=Fibromyalgia; MDD=Major Depressive Disorder, MINI=Mini International Neuropsychiatric Interview, RF=rheumatoid factor, VAS=Visual Analog Scale 24-hour recall pain score